MPM Capital-backed cancer immunotherapy startup Potenza Therapeutics raises $15M

Despite keeping publicly mum about the specifics of its approach, cancer immunotherapy startup Potenza Therapeutics has certainly piqued the attention of investors – it just raised $15 million, according to a regulatory filing. But we don’t know much else yet – just that Potenza’s housed in LabCentral, a biotech innovation hub in Cambridge’s Kendall Square. It’s led by […]

Despite keeping publicly mum about the specifics of its approach, cancer immunotherapy startup Potenza Therapeutics has certainly piqued the attention of investors – it just raised $15 million, according to a regulatory filing.

But we don’t know much else yet – just that Potenza’s housed in LabCentral, a biotech innovation hub in Cambridge’s Kendall Square. It’s led by Daniel Hicklin, a managing director at MPM Capital. And the company recently posted a job listing for a principal scientist, which contained a rather generic company description:

Cancer immunotherapy targeting immune checkpoints is demonstrating transformative anti-tumor activity in clinical use, and additional immune regulatory pathways are emerging with the expectation that therapeutics targeting these pathways will rapidly enter clinical development.  POTENZA Therapeutics Inc. is an exciting start-up biotech, located in the heart of Cambridge MA, focusing on the development of novel biologic agents for the treatment of cancer.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

It also looks like it’s prepping to move out of LabCentral and into a new lab space at 1030 Massachusetts Ave. in Cambridge, as it recently applied for a biosafety permit with the city. Riveting stuff.

The $15 million comes from five investors, and is in the form of both debt and equity. The proposed round was $38 million.